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was assessed by using the SF-36 questionnaire among the
ID subjects and a randomly selected control group of sub-
jects not suffering from ID (520 persons). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. Patients suffering from ID were similar to the
control group in terms of age, sex, and geographic living
area. The annual prevalence of ID was estimated: 8.8%,
IC 95% = [7.8%; 9.8%]. The SF-36 score of mental
health was signiﬁcantly lower in the ID population: 45.8
versus 48.0 in the control group (p < 0,001). The SF-36
score of physical health was not signiﬁcantly different.
CONCLUSION: The annual prevalence of inﬂammatory
dermatitis is estimated at 9% in French adult population.
People suffering from inﬂammatory dermatitis have a sig-
niﬁcant impact on the mental health dimension of quality
of life but not on physical dimension.
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OBJECTIVE: A common approach to the problem of
interpreting the clinical implications of quality of life
(QoL) scores is to utilize the concept of minimal impor-
tant difference (MID). MID emphasises both the primacy
of patient preferences and the relation between QoL
scores and treatment change. The study purpose is to
illustrate how discrete choice analysis (DCA) could be
used to estimate the relation between QoL and patient
preferences for treatment change. METHODS: A 28-item
atopic dermatitis (AD) QoL instrument was applied to
102 subjects enrolled in a pivotal trial comparing two
alternative AD treatments. Four QoL assessments were
made over 12 months. Subjects were also asked to indi-
cate the extent to which the disease was under control.
Their responses were dichotomized into a variable, which
indicated whether subjects were inclined to seek treat-
ment change, or not. DCA was used to estimate the rela-
tion between probability of treatment change and QoL
scores. RESULTS: QoL scores were found to be a statis-
tically signiﬁcant predictor of the probability that a
subject would seek a treatment change (p < 0.0001 in
each case). The sign on the QoL coefﬁcient was in line
with prior expectations. For both treatments, the proba-
bility that a subject would seek a treatment change
declined over time (from 0.63 to 0.42 for active treat-
ment; 0.63 to 0.57 for comparator). However, the prob-
ability for the new treatment under investigation was
lower at the end of the trials than for the comparator.
CONCLUSIONS: While our analysis is illustrative and
exploratory, the results suggest that DCA offers a promis-
ing approach to the interpretation of QoL scores. By
modeling the direct relation between QoL scores and a
patient’s desire for treatment change, the approach dis-
penses with the need for anchor measures, the interpre-
tation of which is often unclear.
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OBJECTIVES: The objective of the analysis is to evalu-
ate the willingness to pay for topical psoriasis treatment
in Denmark. METHODS: A stated preference method—
discrete choice experiment (DCE) was applied as a postal
survey to 700 members of the Danish Psoriasis Associa-
tion. The respondents were asked to choose between two
hypothetical treatment options. The treatment options
were described by six attributes: Number of products, fre-
quency of application, visual effects, non-visual effects,
three types of side effects and monthly cost. Through
logistic regression it was possible to extract the willing-
ness-to-pay of each attribute and for speciﬁc marketed
treatment options (deﬁned by these attributes).
RESULTS: The survey had a high response rate (73%, or
N = 510), and showed the highest willingness-to-pay for
avoidance of two named side effects (irritated skin and
thin skin) followed by visual effect of the treatment. After
adjusting results of the logistic regression model for
income, the willingness to pay for the best possible treat-
ment option relative to the worst possible treatment
option was DKK 4443 (=€597) per month. The willing-
ness to pay for for a newly launched topical treatment
option containing calcipotriol and bethamethasone
(Daivobet) would thus be DKK 4043 (=€543) compared
to an estimated monthly treatment cost of DKK 683 
(=€92). Thus, the societal welfare gain of a month of
Daivobet treatment is DKK 3360 (=€452). CONCLU-
SION: The survey showed high willingness to pay among
a group of Danish psoriasis patients, especially for
avoided side effects and effective treatment. For a single
product (calcipotriol/bethamethasone (Daivobet)), the
willingness-to-pay proved more than fourfold as high as
the treatment cost.
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OBJECTIVES: Evaluating quality-of-life (QoL) of atopic
dermatitis patients and parents of children with atopic
dermatitis as well as patients’ preferences during and after
